Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.

Click here to pay just $5 for a full year of Stealth Trades

Ari Bousbib Biography and Net Worth

Insider of IQVIA

Ari Bousbib is chairman and chief executive officer of IQVIA. He has served in this role since October 2016 following the merger of Quintiles and IMS Health. From 2010 until the merger, Ari was chairman and CEO of IMS Health.

Prior to his appointment at IMS Health, Ari spent 14 years at United Technologies Corporation (UTC), the parent company of Otis Elevator Company, Carrier Corporation, UTC Power, UTC Fire & Security, Pratt & Whitney, Sikorsky Aircraft and Hamilton Sundstrand, where he held several senior leadership positions. Ari joined UTC in 1997 as chief strategy and development officer, became chief operating officer of Otis in 2000 and president and chief executive officer of Otis in 2002. In 2008, Ari was appointed president of UTC Commercial Companies with executive leadership responsibility for the worldwide operations of Otis, Carrier, UTC Fire and Security and UTC Power, generating $36 billion in annual revenues and leading a team of 150,000 employees around the world.

Ari is a former partner at global management and technology consulting firm Booz Allen Hamilton. He joined the firm in 1987 as an associate and was elected to its partnership in 1992.

Ari has been serving on the board of directors of The Home Depot since 2007, and is a member of the Harvard Medical School Health Care Policy Advisory Council. In 2008, Ari was appointed by the President of the United States to serve on the President’s Commission on White House Fellowships.

What is Ari Bousbib's net worth?: The estimated net worth of Ari Bousbib is at least $153.48 million as of March 1st, 2024. Mr. Bousbib owns 796,752 shares of IQVIA stock worth more than $153,478,338 as of November 16th. This net worth evaluation does not reflect any other assets that Mr. Bousbib may own. Additionally, Mr. Bousbib receives a salary of $7,150,000.00 as Insider at IQVIA. Learn More about Ari Bousbib's net worth.
How old is Ari Bousbib?: Mr. Bousbib is currently 63 years old. There are 3 older executives and no younger executives at IQVIA. Learn More on Ari Bousbib's age.
What is Ari Bousbib's salary?: As the Insider of IQVIA Holdings Inc., Mr. Bousbib earns $7,150,000.00 per year. Learn More on Ari Bousbib's salary.
How do I contact Ari Bousbib?: The corporate mailing address for Mr. Bousbib and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on Ari Bousbib's contact information.
Has Ari Bousbib been buying or selling shares of IQVIA?: Ari Bousbib has not been actively trading shares of IQVIA during the last ninety days. Most recently, Ari Bousbib sold 31,678 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a transaction totalling $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares of the company's stock, valued at $199,610,278.56. Learn More on Ari Bousbib's trading history.
Who are IQVIA's active insiders?: IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), and Eric Sherbet (Insider). Learn More on IQVIA's active insiders.
Are insiders buying or selling shares of IQVIA?: In the last year, insiders at the medical research company sold shares 5 times. They sold a total of 55,702 shares worth more than $13,458,663.04. The most recent insider tranaction occured on August, 27th when insider Eric Sherbet sold 1,300 shares worth more than $320,229.00. Insiders at IQVIA own 1.6% of the company. Learn More about insider trades at IQVIA.
Information on this page was last updated on 8/27/2024.

Ari Bousbib Insider Trading History at IQVIA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2024	Sell	31,678	$250.53	$7,936,289.34	796,752
10/12/2020	Sell	69,120	$170.00	$11,750,400.00	721,155
9/15/2020	Sell	46,080	$164.36	$7,573,708.80	698,115
8/14/2020	Sell	69,120	$161.66	$11,173,939.20	721,155
7/22/2020	Sell	46,080	$160.00	$7,372,800.00	698,115
6/1/2020	Sell	19,443	$150.00	$2,916,450.00	671,478
6/28/2019	Sell	96,000	$160.00	$15,360,000.00
6/19/2019	Sell	96,000	$150.00	$14,400,000.00
3/25/2019	Sell	96,000	$140.96	$13,532,160.00
7/26/2018	Sell	368,640	$122.09	$45,007,257.60
6/15/2018	Sell	92,160	$103.20	$9,510,912.00
12/1/2017	Sell	46,080	$101.79	$4,690,483.20
11/1/2017	Sell	46,080	$108.14	$4,983,091.20	1,036,839
10/2/2017	Sell	46,080	$94.91	$4,373,452.80	1,036,839
9/1/2017	Sell	46,080	$95.65	$4,407,552.00	1,036,839
8/7/2017	Sell	92,160	$90.35	$8,326,656.00	1,082,919

Ari Bousbib Buying and Selling Activity at IQVIA

IQVIA Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Today's Range

Now: $192.63

$189.63

$201.52

50 Day Range

MA: $226.95

$192.63

$244.62

2 Week Range

Now: $192.63

$189.63

$261.73

Volume

4,579,132 shs

Average Volume

1,143,450 shs

Market Capitalization

$34.96 billion

P/E Ratio

25.28

Dividend Yield

N/A

Beta

1.51

5 Stocks that could triple in a week

From Traders Agency | Ad

Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.

Click here to pay just $5 for a full year of Stealth Trades

Ari Bousbib Biography and Net Worth

What is Ari Bousbib's net worth?

How old is Ari Bousbib?

What is Ari Bousbib's salary?

How do I contact Ari Bousbib?

Has Ari Bousbib been buying or selling shares of IQVIA?

Who are IQVIA's active insiders?

Are insiders buying or selling shares of IQVIA?